Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P47871
UPID:
GLR_HUMAN
Alternative names:
-
Alternative UPACC:
P47871; Q2M3M5
Background:
The Glucagon receptor, a pivotal G-protein coupled receptor, orchestrates blood glucose regulation through glycogen breakdown and gluconeogenesis. It is essential for glucose homeostasis and fasting responses, activating adenylate cyclase and engaging in phosphatidylinositol-calcium signaling.
Therapeutic significance:
Linked to Mahvash disease, a disorder stemming from gene variants affecting this receptor, it presents a unique target for therapeutic intervention. Understanding the Glucagon receptor's role could unveil new strategies for managing glucose-related disorders.